Evidence map›Paper›PMID 34581016›Full record

ArticleJournal of hepato-biliary-pancreatic sciences2022

New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS).

Atsushi Oba, Marco Del Chiaro, Sohei Satoi, Sun-Whe Kim, Hidenori Takahashi, Jun Yu, Masayoshi Hioki, Masayuki Tanaka, Yoshiyasu Kato, Kyohei Ariake and 11 more

Open access · greenAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Journal of hepato-biliary-pancreatic sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 5 countries.

Atsushi ObaDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-7315-0830
Marco Del ChiaroDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Sohei SatoiDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0001-6527-5409
Sun-Whe KimDepartment Surgery, Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Hidenori TakahashiDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Jun YuDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Masayoshi HiokiDepartment of Surgery, Fukuyama City Hospital, Hiroshima, Japan.
Masayuki TanakaDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany.
Yoshiyasu KatoDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kyohei AriakeDepartment of Surgery, Tohoku University, Sendai, Japan.
Y H Andrew WuDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Yosuke InoueDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5812-6608
Yu TakahashiDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3066-023X
Thilo HackertDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany.
Christopher L WolfgangDepartment of Surgery, New York University Langone Health, New York, New York, USA.
Marc G BesselinkDepartment of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Richard D SchulickDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Yuichi NagakawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1169-8160
Shuji IsajiDirector of Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0000-0001-7868-4498
Akihiko TsuchidaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University Graduate School Medicine, Yokohama, Japan.ORCID https://orcid.org/0000-0001-5520-8114
Japanese Foundation For Cancer Research · JPJohns Hopkins University · USTokyo Medical University · JPUniversity of Colorado Anschutz Medical Campus · USAmsterdam Neuroscience · NLFukuyama City Hospital · JPHeidelberg University · DEKansai Medical University · JPKeio University · JPMie University · JPNagoya University · JPNational Cancer Center · USNYU Langone Health · USOsaka International Cancer Institute · JPTohoku University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symposium "New criteria of resectability for pancreatic cancer" was held during the 33nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) in 2021 to discuss the potential modifications that could be made in the current resectability classification. The meeting focused on setting the foundation for developing a new prognosis-based resectability classification that is based on the tumor biology and the response to neoadjuvant treatment (NAT). The symposium included selected experts from Western and Eastern high-volume centers who have discussed their concept of resectability status through published literature. During the symposium, presenters reported new resectability classifications from their respective institutions based on tumor biology, conditional status, pathology, and genetics, in addition to anatomical tumor involvement. Interestingly, experts from all the centers reached the agreement that anatomy alone is insufficient to define resectability in the current era of effective NAT. On behalf of the JSHBPS, we would like to summarize the content of the conference in this position paper. We also invite global experts as internal reviewers of this paper for intercontinental cooperation in creating an up-to-date, prognosis-based resectability classification that reflects the trends of contemporary clinical practice.

Indexed as

Biliary Tract Surgical ProceduresPancreatic NeoplasmsHumansJapanNeoadjuvant TherapyCA19-9Eastern Cooperative Oncology Group performance statusInternational Consensusmaximum standardized uptake values (SUVmax)modified Glasgow Prognostic Scoreneoadjuvant treatmentpancreatic cancerresectabilitythe 18-fluorodeoxyglucose positron emission tomography/computed tomographythe International Association of Pancreatologythe Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS)the National Comprehensive Cancer Network guidelines

Identifiers

PMID34581016
OpenAlexW3204852424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.